ECCO 2022 Highlights Podcast

In this episode (17:15 min), Medicom’s correspondent covers 6 presentations from the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO’22), which was held as a virtual event from 16-19 February 2022.

1. Mirikizumab safe and efficacious for active UC
   Mirikizumab was more efficacious than placebo as induction therapy for participants with active ulcerative colitis (UC). In addition, the safety profile of mirikizumab was favourable. These results from the phase 3 LUCENT-1 trial support the applicability of mirikizumab in patients with UC.
2. Upadacitinib maintenance therapy delivers sustained improvements in active UC
   Upadacitinib maintenance therapy was associated with sustained improvements in abdominal pain, bowel urgency, and fatigue in patients with moderately to severely active ulcerative colitis (UC) who responded to upadacitinib induction therapy. Numerical benefits were observed for the high-dose maintenance group over the low-dose maintenance group. These are the main results of a study investigating secondary endpoints of the U-ACHIEVE maintenance trial.
3. Vedolizumab first approved therapy for chronic pouchitis
   Vedolizumab showed clinical, endoscopic, and histologic benefits over placebo in patients with chronic pouchitis after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). The safety profile of vedolizumab was consistent with previous data published on this agent. The phase 4 EARNEST trial is the first and largest randomised controlled trial to demonstrate significant benefits of a biologic therapy in patients with chronic pouchitis.
4. Benefits of segmental colectomy over total colectomy
   Segmental colectomy (SC) was not associated with an increased risk of surgical recurrence compared with total colectomy (TC) in participants with Crohn’s disease (CD). In addition, SC did reduce the risk of a temporary or permanent stoma. The large-scale international, multicentre SCOTCH study adds high-quality data to the understanding of colectomy in CD.
5. Stopping infliximab, but not anti-metabolites, leads to more relapses in CD
   In patients with Crohn’s disease (CD) who achieved sustained remission on infliximab plus anti-metabolite therapy, infliximab discontinuation was associated with an increased risk of relapse. In contrast, anti-metabolite discontinuation did not lead to significantly higher relapse rates compared to continuation of the combination treatment. Since physicians often contemplate de-escalation of infliximab plus anti-metabolite therapy, these results may add to the decision-making process of treatment de-escalation in patients with CD.
6. RESTORE-UC: No better outcomes with FMT superdonors than with autologous stools
   The use of superdonor stools for faecal microbiota transplantation (FMT) did not outperform autologous stools in initiating remission in patients with active ulcerative colitis (UC). Furthermore, the current RESTORE-UC trial presented an FMT anaerobic preparation and administration protocol to improve the international standardisation of this therapy.

Enjoy listening!

 



Posted on 8 March 202227 November 2024